Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate to severe stable Chronic Obstructive Lung Disease (COPD) Stage II or Stage III according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines.~* Patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 30 % and/or \<80 % of the predicted normal, and a post-bronchodilator FEV1/Forced Vital Capacity (FVC) \< 0.70 at screening.~* Current or ex-smokers who have a smoking history of at least 10 pack years~* Symptomatic patients according to daily diary data.~Exclusion Criteria:~* Pregnant or nursing (lactating) women.~* Women of child-bearing potential unless using adequate contraception.~* Patients with Type I or uncontrolled Type II diabetes.~* Patients with a history of long time interval between start of Q wave and end of T wave in the heart's electrical cycle (QT) syndrome or whose QT corrected for heart rate (QTc) measured at screening (Visit 2) (Fridericia's method) is prolonged~* Patients with paroxysmal (e.g. intermittent) atrial fibrillation~* Patients who have a clinically significant electrocardiogram (ECG) or laboratory abnormality at screening (Visit 2)~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVA237 + indacaterol (Type: ACTIVE_COMPARATOR): None
- Placebo to NVA237 + indacaterol (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).